NCT01565928View on ClinicalTrials.gov

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

January 24, 2012

Primary Completion Date

July 1, 2013

Study Completion Date

February 26, 2018

Conditions

Prostate Cancer

Interventions

DRUG

MDV3100

4 x 40 mg capsules, orally, once per day

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan-Kettering Cancer Center, New York

23502

Virginia Oncology Associates, Norfolk

Sponsors

Lead Sponsor

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Pfizer

INDUSTRY